SMPDL3B

Across TCGA pan-cancer cohorts, SMPDL3B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMPDL3B data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SMPDL3B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SMPDL3B expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, SARC, and UCEC are the cancer types where SMPDL3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	1.000	0.271	.041	7	view →
SARC	DFS	Median	All	0.094	0.591	.004	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.426	0.795	.008	4	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMPDL3B–BLCA (DFS)

Open the BLCA breakdown →